The Multinational Association of Supportive Care in Cancer (MASCC) shared on LinkedIn:
“In this Supportive Care Digest, Dr. Mélanie Janson provides an overview of the POSITIVE study (Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine-Responsive Breast Cancer).
Take home message: Pregnancy and temporary interruption of endocrine therapy appears to be safe and may be considere during the adjuvant phase of HR+ breast cancer.”
Title: Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial
Authors: O. Pagani, S.M. Niman, M. Ruggeri, F.A. Peccatori, H.A. Azim Jr, M. Colleoni, C. Saura, C. Shimizu, A.B. Sætersdal, J.R. Kroep, E. Warner, F. Amant, A. Mailliez, H.C.F. Moore, M. Ruiz-Borrego, J.M. Walshe, V.F. Borges, A. Gombos, A. Kataoka, C. Rousset-Jablonski, A.H. Partridge
Read the Full Article.
Other articles from The Multinational Association of Supportive Care in Cancer on OncoDaily.